PeptideSearch

FOXO4-DRI

Very early research

Get notified when the evidence changes.

The research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04

Also called FOXO4 D-Retro-Inverso / Proxofim

Designed to clear out old, damaged cells. Studied only in cells and mice so far.

Official status: Not nominated for 503A compounding · Checked 2026-08-04

Can a doctor prescribe this?

Small pharmacy (503A)
Never put forward to FDA
Large outsourcing facility (503B)
Never put forward to FDA

Not approved and not on the compounding list.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

Lab suppliers we list: 5

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

No dosing information has been published in the research indexed here.

Spot an error? corrections@peptidesearch.org

We'll email you when a new study, trial or status change lands for FOXO4-DRI. Unsubscribe in one click.